3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
fludarabine
3
Cyclophosphamide
3
pembrolizumab
2
entinostat
2
aldesleukin
2
Trastuzumab
2
Nivolumab
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
tipifarnib
1
oncogene protein E7, Human papillomavirus type 16
1
nanocis
1
bintrafusp alfa protein, human
1
Vorinostat
1
Technetium-99
1
Specimen Handling
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Observation
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Infracyanine green
1
Indocyanine Green
1
Indinavir
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
nanocis
×
Head & Neck
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled